What are the indications, dosing regimen, contraindications, adverse effects, and monitoring recommendations for elobixibat in adults with chronic constipation, including constipation‑predominant irritable bowel syndrome and opioid‑induced constipation?

Elobixibat for Chronic Constipation

Elobixibat is an ileal bile acid transporter (IBAT) inhibitor that is effective and safe for chronic constipation, dosed at 10 mg once daily before breakfast, with the option to titrate between 5-15 mg based on response and tolerability.

Indications

Elobixibat is indicated for chronic constipation (functional constipation) in adults. The drug works by inhibiting bile acid reabsorption in the ileum, increasing colonic bile acid concentrations, which stimulates both fluid secretion and colonic motility 1, 2. This mechanism is particularly beneficial for patients with:

• Severe constipation associated with slow colonic transit 1
• Reduced fecal bile acid excretion 1
• Inadequate response to conventional laxatives 2

Important limitation: The available evidence does not support elobixibat for constipation-predominant IBS (IBS-C) or opioid-induced constipation—these conditions were not studied in the clinical trials. For IBS-C specifically, guidelines recommend linaclotide, plecanatide, or lubiprostone instead 3, 4.

Dosing Regimen

Standard dose: 10 mg once daily before breakfast 5, 2, 6

Dosing Algorithm:

• Start: 10 mg once daily before breakfast
• Titrate down to 5 mg if patient experiences diarrhea or abdominal discomfort 2, 7
• Titrate up to 15 mg if inadequate response after 1-2 weeks 2
• Timing is critical: Must be taken before breakfast—food reduces systemic absorption by 80% while paradoxically increasing the therapeutic effect by raising plasma C4 levels (a marker of bile acid synthesis) 5

Onset and Duration:

• First bowel movement typically occurs within 20-24 hours 8
• Significant improvement in bowel frequency by week 1-2 2, 6
• Sustained efficacy demonstrated for 52 weeks of continuous use 2, 6

Contraindications

While formal contraindications are not explicitly detailed in the research evidence, avoid or use with extreme caution in:

• Mechanical gastrointestinal obstruction (similar to other secretagogues)
• Severe hepatobiliary disease (drug affects bile acid metabolism)
• Severe diarrheal disorders (would exacerbate symptoms)

Adverse Effects

Most common adverse effects are gastrointestinal and dose-dependent 2, 6:

Frequent (>10%):

• Abdominal pain: 19-24% 2, 6
• Diarrhea: 13-15% 2, 6

Less Common (3-10%):

• Mild gastrointestinal symptoms 6

Key Safety Points:

• Overall adverse drug reaction rate: 6.35% at 4 weeks, 5.40% at 52 weeks 6
• Most adverse events are mild and transient 2, 6
• No serious adverse drug reactions reported in large postmarketing surveillance (3,638 patients) 6
• Lower adverse event rates in elderly patients: 5.49% in ≥65 years, 4.85% in ≥75 years, 2.80% in ≥85 years 6
• One case of moderate inguinal hernia reported (unclear causality) 2
• Safe in patients with psychiatric comorbidities (schizophrenia, depression) with no new safety signals 9

Management of Adverse Effects:

• If diarrhea occurs: Reduce dose to 5 mg daily 2, 7
• If abdominal pain is problematic: Reduce dose or temporarily discontinue
• Symptoms typically resolve with dose adjustment 8, 7

Monitoring Recommendations

Efficacy Monitoring:

• Bowel movement frequency: Target 5-7+ spontaneous bowel movements per week 2, 6
• Bristol Stool Form Scale (BSFS): Target type 3-5 (ideal is type 4) 6, 7
• Assessment timeline:
  • Week 2: Initial efficacy assessment 6, 7
  • Week 4: Full response evaluation 2, 6
  • Ongoing: Monitor for sustained benefit

Safety Monitoring:

• No routine laboratory monitoring required 6
• Monitor for gastrointestinal symptoms (diarrhea, abdominal pain)
• Patient satisfaction assessment at weeks 2,4, and periodically thereafter 6

Special Populations:

Elderly patients (≥65 years):

• No dose adjustment needed 6, 7
• Actually showed better tolerability than younger patients 6
• Mean age in postmarketing surveillance was 70.8 years with 73.7% ≥65 years 6
• Efficacy and safety comparable to younger patients 7

Patients on psychotropic medications:

• Safe and effective in patients taking antipsychotics (85-95% of psychiatric cohort) 9
• No drug interactions noted with anxiolytics or sedative-hypnotics 9

Clinical Pearls

• Elobixibat increases colonic bile acid concentrations, providing both osmotic and prokinetic effects 1
• Efficacy correlates with plasma C4 levels (bile acid synthesis marker) 5
• 62.5% of patients use elobixibat as monotherapy; 37.5% use concomitant laxatives 6
• Patient satisfaction reaches 90.4% by week 52 6
• May be particularly useful as rescue therapy for medication-induced constipation (e.g., incretin-based therapies like tirzepatide) 8
• Minimal systemic absorption makes it suitable for long-term use 5